Latest News
-
Mandatory Testing for Indian Spices Destined for Singapore, Hong Kong After Ban -
TRAI Advocates for Enhanced Telecom Infrastructure Sharing Among Licensees -
LTIMindtree Reports Slight Q4 Profit Dip, Optimistic About Upcoming Growth -
Axis Bank Announces Q4 Net Profit at Rs 7,599 Crore Amid Deposit Accretion Worries -
hBits Expands to Pune with CyberCity Magarpatta Acquisition, Eyes Investment Opportunities -
India's First Green Hydrogen Pilot Project Goes Live at Nathpa Jhakri -
DCB Bank Q4 Results: PAT Grew 9% To Rs 156 Cr, NII Jumps 4.5%; Dividend Declared -
RBI Halts New Customer Onboarding at Kotak Mahindra Bank Over IT Compliance -
Macrotech Developers' Annual Profit Triples Despite Q4 Dip -
DoT Engages TRAI for Equitable Satcom Spectrum Allocation Guidelines
For Daily Alerts
Strides Shasun Shares Gain On US FDA Nod
Shares in Strides Shasun gained ground after the company received US FDA Nod. The company said said it received approval from the US Food and Drug Administration for cetirizine hydrochloride capsules, used to relieve allergy symptoms.
The company said the product will be manufactured at its facility in Bengaluru and is ready for launch. Quoting IRI data, Strides Shasun said the US market for cetirizine hydrochloride capsules is approximately USD 60 million, with only one other generic player. Shares of the company were trading 0.16 per cent higher at Rs 1,089 on BSE.
Goodreturns.in
Story first published: Monday, July 24, 2017, 12:16 [IST]
